专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP4215194A1 COMBINATION THERAPY 审中-实审
公开(公告)号：EP4215194A1
公开(公告)日：2023-07-26
申请号：EP23161550.1
申请日：2012-01-11
申请人： Dimerix Bioscience Pty Ltd
发明人： PFLEGER, Kevin Donald George , MCCALL, Elizabeth , WILLIAMS, James
IPC分类号： A61K31/41 , A61K31/80 , A61P9/06 , A61K31/537 , A61P9/00 , A61P9/12 , A61P13/12
摘要： The invention relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof, and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof; and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof which inhibits a component of the chemokine receptor pathway other than the chemokine receptor. Oral sustained release pharmaceutical compositions comprising the pharmaceutical composition, as well as injectable sustained release pharmaceutical compositions comprising the pharmaceutical composition are described. The invention further relates to tablets, capsules, injectable suspensions, and compositions for pulmonary or nasal delivery comprising the pharmaceutical composition. Also described are: methods for assessing the efficacy of the pharmaceutical composition; methods for assessing the inhibition or partial inhibition activity of the pharmaceutical composition; methods for the treatment, amelioration or prevention of a condition or disease comprising administering to a subject a therapeutically effective amount of the pharmaceutical composition; and the use of the pharmaceutical composition for the manufacture of a dosage form for the treatment of a disease.

2. 发明授权

EP2663304B1 COMBINATION THERAPY 有权
公开(公告)号：EP2663304B1
公开(公告)日：2019-11-20
申请号：EP12734251.7
申请日：2012-01-11
申请人： Dimerix Bioscience Pty Ltd
发明人： PFLEGER, Kevin Donald George , MCCALL, Elizabeth , WILLIAMS, James
IPC分类号： A61K31/41 , A61K31/80 , A61P9/06 , A61K31/537 , A61P9/00 , A61P9/12 , A61P13/12

3. 发明公开

EP2663304A1 COMBINATION THERAPY 有权
标题翻译：联合治疗
公开(公告)号：EP2663304A1
公开(公告)日：2013-11-20
申请号：EP12734251.7
申请日：2012-01-11
申请人： Dimerix Bioscience Pty Ltd
发明人： PFLEGER, Kevin Donald George , MCCALL, Elizabeth , WILLIAMS, James
IPC分类号： A61K31/41 , A61K31/80 , A61P9/06 , A61K31/537 , A61P9/00 , A61P9/12 , A61P13/12
摘要： The invention relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof, and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof; and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof which inhibits a component of the chemokine receptor pathway other than the chemokine receptor. Oral sustained release pharmaceutical compositions comprising the pharmaceutical composition, as well as injectable sustained release pharmaceutical compositions comprising the pharmaceutical composition are described. The invention further relates to tablets, capsules, injectable suspensions, and compositions for pulmonary or nasal delivery comprising the pharmaceutical composition. Also described are: methods for assessing the efficacy of the pharmaceutical composition; methods for assessing the inhibition or partial inhibition activity of the pharmaceutical composition; methods for the treatment, amelioration or prevention of a condition or disease comprising administering to a subject a therapeutically effective amount of the pharmaceutical composition; and the use of the pharmaceutical composition for the manufacture of a dosage form for the treatment of a disease.
摘要翻译：本发明涉及药物组合物，其包含：（a）至少一种血管紧张素受体阻断剂或其药学上可接受的盐，和（b）至少一种趋化因子受体途径抑制剂或其药学上可接受的盐。本发明还涉及药物组合物，其包含：（a）至少一种血管紧张素受体阻断剂或其药学上可接受的盐; 和（b）至少一种趋化因子受体途径抑制剂或其药学上可接受的盐，其抑制除趋化因子受体以外的趋化因子受体途径的成分。描述了包含该药物组合物的口服持续释放药物组合物，以及包含该药物组合物的可注射缓释药物组合物。本发明进一步涉及包含该药物组合物的用于肺部或鼻腔递送的片剂，胶囊剂，可注射悬浮液和组合物。还描述了：用于评估药物组合物功效的方法; 评估药物组合物的抑制或部分抑制活性的方法; 用于治疗，改善或预防病症或疾病的方法，其包括向受试者施用治疗有效量的药物组合物; 以及该药物组合物用于制造用于治疗疾病的剂型的用途。

4. 发明公开

EP3586844A1 COMBINATION THERAPY 审中-公开
公开(公告)号：EP3586844A1
公开(公告)日：2020-01-01
申请号：EP19186903.1
申请日：2012-01-11
申请人： Dimerix Bioscience Pty Ltd
发明人： PFLEGER, Kevin Donald George , MCCALL, Elizabeth , WILLIAMS, James
IPC分类号： A61K31/41 , A61K31/80 , A61P9/06 , A61K31/537 , A61P9/00 , A61P9/12 , A61P13/12
摘要： The invention relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof, and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof; and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof which inhibits a component of the chemokine receptor pathway other than the chemokine receptor. Oral sustained release pharmaceutical compositions comprising the pharmaceutical composition, as well as injectable sustained release pharmaceutical compositions comprising the pharmaceutical composition are described. The invention further relates to tablets, capsules, injectable suspensions, and compositions for pulmonary or nasal delivery comprising the pharmaceutical composition. Also described are: methods for assessing the efficacy of the pharmaceutical composition; methods for assessing the inhibition or partial inhibition activity of the pharmaceutical composition; methods for the treatment, amelioration or prevention of a condition or disease comprising administering to a subject a therapeutically effective amount of the pharmaceutical composition; and the use of the pharmaceutical composition for the manufacture of a dosage form for the treatment of a disease.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式